CORRECTING and REPLACING IASO Receives NMPA Acceptance of its First Indication IND Application for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy
PLEASANTON, Calif. & NANJING, China--(BUSINESS WIRE)--#Biopharmaceutical--First sentence of release should read: "...has been accepted by…